2상모집 중

Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML

연구 개요

This phase II trial tests how well VA alternating with low-dose CHA works in treating unfit patients with newly diagnosed acute myeloid leukemia (AML). This is a prospective, multi-centers, single arm phase II study aimed to overcome VEN resistance and achieve greater MRD negative rate, providing better control of treatment for unfit AML.

스폰서: 협력: 애브비
적응증: Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
중재: Alternately treated with VA/low CHA regimen
목표 등록: 25명
시작일: 2025-09-16
완료(예정): 2029-07-31
등록번호: NCT07172204 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.